The short version of GW501516 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 317318-70-0 | Unique identifier for the compound. |
| Chemical class | PPARδ agonist | Synthetic ligand for peroxisome proliferator-activated receptor delta. |
| Appearance | White to off-white solid | Typical form of research-grade material. |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water. |
| Typical storage | -20°C | Recommended for long-term storage of stock solutions. |
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
== Personal life and education == Anagani Satya Prasad (born January 10, 1972) was son of Anagani Ranga Rao. He was the relative of Anagani Bhagavantha Rao who was elected as MLA from Kuchinapudi constituency and served as minister in 1970–80s. Though his family was native of Cherukuapalli mandal, Satya Prasad childhood and education happened in Hyderabad city itself. His educational qualifications are as follows. He was unmarried as of June 2024 as per affidavit submitted for elections.
==== Cysteine ==== Sulfide is incorporated into cysteine, catalyzed by O-acetylserine (thiol)lyase, with O-acetylserine as substrate. The synthesis of O-acetylserine is catalyzed by serine acetyltransferase and together with O-acetylserine (thiol)lyase it is associated as enzyme complex named cysteine synthase. The formation of cysteine is the direct coupling step between sulfur (sulfur metabolism) and nitrogen assimilation in plants. This differs from the process in yeast, where sulfide must be incorporated first in homocysteine then converted in two steps to cysteine. Cysteine is sulfur donor for the synthesis of methionine, the major other sulfur-containing amino acid present in plants. This happens through the transsulfuration pathway and the methylation of homocysteine. Both cysteine and methionine are sulfur-containing amino acids and are of great significance in the structure, conformation and function of proteins and enzymes, but high levels of these amino acids may also be present in seed storage proteins. The thiol groups of the cysteine residues in proteins can be oxidized resulting in disulfide bridges with other cysteine side chains (and form cystine) and/or linkage of polypeptides. Disulfide bridges (disulfide bonds) make an important contribution to the structure of proteins. The thiol groups are also of great importance in substrate binding of enzymes, in metal-sulfur clusters in proteins (e.g. ferredoxins) and in regulatory proteins (e.g. thioredoxins).
Anti-metabolites are a group of molecules that impede DNA and RNA synthesis. Many of them have a similar structure to the building blocks of DNA and RNA. The building blocks are nucleotides; a molecule comprising a nucleobase, a sugar and a phosphate group. The nucleobases are divided into purines (guanine and adenine) and pyrimidines (cytosine, thymine and uracil). Anti-metabolites resemble either nucleobases or nucleosides (a nucleotide without the phosphate group), but have altered chemical groups. These drugs exert their effect by either blocking the enzymes required for DNA synthesis or becoming incorporated into DNA or RNA. By inhibiting the enzymes involved in DNA synthesis, they prevent mitosis because the DNA cannot duplicate itself. Also, after misincorporation of the molecules into DNA, DNA damage can occur and programmed cell death (apoptosis) is induced. Unlike alkylating agents, anti-metabolites are cell cycle dependent. This means that they only work during a specific part of the cell cycle, in this case S-phase (the DNA synthesis phase). For this reason, at a certain dose, the effect plateaus and proportionally no more cell death occurs with increased doses. Subtypes of the anti-metabolites are the anti-folates, fluoropyrimidines, deoxynucleoside analogues and thiopurines. The anti-folates include methotrexate and pemetrexed. Methotrexate inhibits dihydrofolate reductase (DHFR), an enzyme that regenerates tetrahydrofolate from dihydrofolate. When the enzyme is inhibited by methotrexate, the cellular levels of folate coenzymes diminish.
The Kozak consensus sequence (Kozak consensus or Kozak sequence) is a nucleic acid motif that functions as the protein translation initiation site in most transcripts of archaeal and eukaryotic mRNA. Archaeal transcriptomes use a mix of Kozak sequence, leaderless initiation and, more rarely, the Shine–Dalgarno sequence. Most of the initiation, elongation, and termination factors in archaea have homologs in eukaryotes. Regarded as the optimum sequence for initiating translation in eukaryotes, the sequence is an integral aspect of protein regulation and overall cellular health as well as having implications in human disease. It ensures that a protein is correctly translated from the genetic message, mediating ribosome assembly and translation initiation. A wrong start site can result in non-functional proteins. As it has become more studied, expansions of the nucleotide sequence, bases of importance, and notable exceptions have arisen. Haloarchaea are known to have a variant of the Kozak consensus sequence in their Hsp70 genes. The sequence was named after the scientist who discovered it, Marilyn Kozak. Kozak discovered the sequence through a detailed analysis of DNA genomic sequences. The Kozak sequence is not to be confused with the ribosomal binding site (RBS), that being either the 5′ cap of a messenger RNA or an internal ribosome entry site (IRES).
== Research == As of June 2025, suvomipic is in phase 2 clinical trials for treatment of alopecia. Two clinical trials have been completed, including a phase 1 trial and a phase 2a trial. There were initial concerns that suvomipic might actually kill all hair follicles rather than promote hair growth, but its developers were pleased to find that this was not the case. The effectiveness data for a phase 2a trial was released in June 2025. In this preliminary trial, 31% of men with "advanced baldness" or "a higher degree of hair loss" experienced an increase in hair density of 20% or more at the 8-week follow-up point subsequent to 4 weeks of suvomipic treatment, whereas none of the men in the placebo group showed improvement. Existing hair-loss drugs like minoxidil and finasteride are said to require months to produce any visible difference. The new hair growth was described as not being vellus hair, peach fuzz, or baby hair, but as being proper and thick terminal hair, and to have grown in previously bald areas. However, Pelage Pharmaceuticals declined to share before-and-after photos, citing regulations preventing them from doing so. Moreover, the trial was a short-term study that was primarily designed to assess safety and not efficacy. A three-month open-label extension of the phase 2a trial was subsequently completed and these data will be shared in 2026.
Sources: en.wikipedia.org
=== ITV === In 2007, Willis presented ITV2 spin-off series I'm a Celebrity...Get Me Out of Here! NOW! with her husband Matt before departing in 2008. She presented numerous episodes of The Hot Desk on ITV2 between 2008 and 2014. In September 2012, Willis became a permanent presenter on This Morning, presenting segments in The Hub, taking over from Coleen Nolan. The feature was axed in 2014. She was also a stand-in presenter on the main show when Holly Willoughby or Ruth Langsford were absent and returned to guest present the show with Rylan Clark-Neal in 2018. Willis hosted two series of the ITV2 reality show Girlfriends in 2012 and 2013. On 16 November 2012, Willis was a guest anchor Loose Women and has since presented on several occasions as a stand-in presenter. In November 2013, Willis guest presented an episode of The Paul O'Grady Show while O'Grady was away. In June 2013, Willis co-presented the ITV game show Prize Island with Alexander Armstrong. In February 2015, Willis was a team captain on the six-part ITV2 comedy panel show Reality Bites, hosted by Stephen Mulhern. On 2 July 2015, it was announced that Willis would present a new three-part series for ITV called What Would Be Your Miracle, about modern miracles. The series began on 28 April 2016. In January 2017, The Voice UK moved from BBC One to ITV. It was confirmed on 9 June 2016 that Willis would present the series after co-hosting three previous series on the BBC. She also presented two series of The Voice Kids on ITV since 2017. In January 2017, she presented The BRITs Are Coming live on ITV.
=== 1990–1998: Early modeling and television roles === Larter began her modeling career at the age of 14 when a modeling scout discovered her on the street and asked her to star in a Philadelphia Phillies commercial. That led to a modeling contract with the prestigious Ford Modeling Agency in Manhattan, New York. Larter subsequently skipped her senior year to model in Australia, Italy, and Japan; Japan being a country she temporarily lived in at 17. While modeling in Italy, Larter met fellow model and aspiring actress Amy Smart and the two "became instant friends", according to Larter. In November 1996, Larter portrayed fictional actress Allegra Coleman in an Esquire magazine hoax. When speaking about the cover and her fame, Larter said, "When the door opens for you in Hollywood, you need to run with it. You know?" Larter is signed to IMG Models. She landed her first professional acting roles in 1997 when she appeared in several television programs. She appeared in "The Ways and Means", an episode of the NBC television series Suddenly Susan starring Brooke Shields, and the short-lived series Chicago Sons also on NBC. The roles were followed by a number of other appearances on Dawson's Creek on The WB, CBS' Chicago Hope, and Just Shoot Me! on NBC.
Autoimmune diseases represent a vast and diverse category of disorders that, despite their differences, share some common symptomatic threads. These shared symptoms occur as a result of the body's immune system mistakenly attacking its own cells and tissues, causing inflammation and damage. However, due to the broad range of autoimmune diseases, the specific presentation of symptoms can significantly vary based on the type of disease, the organ systems affected, and individual factors such as age, sex, hormonal status, and environmental influences. An individual may simultaneously have more than one autoimmune disease (known as polyautoimmunity), further complicating the symptomatology.
==== Effect on gene expression ==== Differing mechanical properties in ECM exert effects on both cell behaviour and gene expression. Although the mechanism by which this is done has not been thoroughly explained, adhesion complexes and the actin-myosin cytoskeleton, whose contractile forces are transmitted through transcellular structures are thought to play key roles in the yet to be discovered molecular pathways.
Sources: en.wikipedia.org
== Advantages and limitations == First, a greatly reduced search space will decrease the searching time. Second, by taking full advantage of all spectral features including relative fragment intensities, neutral losses from fragments and various additional specific fragments, the process of spectra searching will be more specific, and it will generally provide better discrimination between true and false matches. Spectral library searching is not applicable in a situation where the discovery of novel peptides or proteins is the goal. However, more and more high-quality mass spectra are being acquired by the collective contribution of the scientific community, which will continuously expand the coverage of peptide spectral libraries.
Worth stated that "many secular-minded Yemenis seem unsure whether to view the Houthis as oppressors or potential allies." In general, the Houthis' policies are often decided on a local basis, and high-ranking Houthi officials are frequently incapable of checking regional officers' powers, making the treatment of civilians dependent on the area.
=== Light transmission aggregometry === In light transmission aggregometry (LTA), platelet-rich plasma is placed between a light source and a photocell. Unaggregated plasma allows relatively little light to pass through. After adding an agonist, the platelets aggregate, increasing light transmission, which is detected by a photocell.
=== Social groups === China Agricultural Means of Production Association China ASEAN Agricultural Materials Association China Cotton Association China Fruit Marketing Association China Tea Circulation Association China Edible Fungi Association China Renewable Resources Recycling and Utilization Association China Society of Supply and Marketing Cooperative Economics China Cotton and Hemp Circulation Economy Research Association Northeast Information Association
After being elected in November 2024, Trump said he wished to end the Gaza war, telling Israeli prime minister Benjamin Netanyahu to end Israel's invasion within two months and warning Hamas that they would have "all hell to pay" if they did not agree to a ceasefire and release all hostages by Trump's inauguration. Trump's incoming administration joined the Biden administration in pressuring negotiations, and Israel and Hamas agreed to a phased ceasefire on January 15, 2025. In February 2025, Trump proposed an American takeover of Gaza in which the territory's Palestinian population would be relocated to allow for its redevelopment, which was criticized by Egypt and Jordan. The ceasefire lasted until March 18, when Israel launched attacks on Gaza. Trump's special envoy Steve Witkoff blamed Hamas for renewed fighting in Gaza. On May 16, while in Abu Dhabi, United Arab Emirates, Trump said, "We're looking at Gaza. And we're going to get that taken care of. A lot of people are starving." This is an area of tension between President Trump and Prime Minister Benjamin Netanyahu. Israel claims that Hamas systemically raids food aid in order to support its operations, and Israel has put forward a plan of food distributed through a system of hubs run by private contractors and protected by Israeli soldiers. The U.S.-backed Gaza Humanitarian Foundation has been set up to carry out this plan and announced it would be ready to begin operations by the end of May. On July 28, while in Scotland, President Trump said he believed there was starvation occurring in Gaza.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.
No. Cardarine is not an anabolic steroid; it belongs to a different chemical class that targets PPARδ. Steroids act primarily through androgen receptors, while cardarine acts through a nuclear receptor involved in metabolism.
Some rodent studies reported increased endurance and changes in fat metabolism after cardarine exposure. Long-term studies in animals also raised concerns about cancer in certain tissues. Human trial data are limited, so these findings cannot be directly translated to people.
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.